📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Haleos Labs Q3 FY26 Consolidated Net Profit Rises 37% YoY to ₹6.65 Cr; Revenue Up 12%
Haleos Labs Limited (formerly SMS Lifesciences) reported a strong consolidated performance for Q3 FY26, with revenue growing 12% YoY to ₹94.78 crore. Consolidated net profit surged 37% YoY to ₹6.65 crore, driven by improved operational efficiencies and lower finance costs. The board also approved a corporate guarantee for its subsidiary, Mahi Drugs, to facilitate External Commercial Borrowing (ECB), indicating potential expansion plans. While standalone revenue saw a slight dip, the consolidated numbers reflect robust growth from subsidiary operations.
Key Highlights
Consolidated Revenue from Operations increased 12% YoY to ₹94.78 crore from ₹84.60 crore.
Consolidated Net Profit grew 37% YoY to ₹6.65 crore compared to ₹4.85 crore in Q3 FY25.
Consolidated EPS rose to ₹21.89 for the quarter, up from ₹18.08 in the corresponding previous year quarter.
Finance costs on a consolidated basis decreased to ₹1.54 crore from ₹2.14 crore YoY.
Board approved a corporate guarantee for subsidiary Mahi Drugs for External Commercial Borrowing, subject to shareholder approval.
💼 Action for Investors
Investors should view the strong consolidated profit growth and debt reduction in finance costs as positive indicators. Monitor the upcoming postal ballot regarding the corporate guarantee for Mahi Drugs as it signals future capital expenditure or expansion.
Haleos Labs Partners with HRV Global for Orphan Drug and Niche API Manufacturing
Haleos Labs Limited has entered into a strategic development collaboration with HRV Global Life Sciences to accelerate the manufacturing of orphan drugs and niche therapeutic APIs. The partnership combines Haleos' USFDA-GMP aligned manufacturing expertise with HRV Global's international regulatory and market access capabilities. This initiative targets high-value, underserved therapeutic segments in major regulated markets including the US and EU. The collaboration is designed to strengthen the company's global footprint across Latin America, MENA, and APAC regions through coordinated development pathways.
Key Highlights
Strategic collaboration with HRV Global Life Sciences for orphan drug and niche therapeutic APIs
Leverages Haleos' USFDA-GMP manufacturing systems for high-value complex molecules
Targets expansion into regulated and semi-regulated markets including US, EU, and Latin America
Focuses on underserved therapeutic segments to improve product mix and margins
HRV Global to lead regulatory execution and global market access initiatives
💼 Action for Investors
Investors should view this as a positive move toward high-margin niche segments; monitor for specific product pipeline updates and regulatory filings in the US and EU markets.